| Bioactivity | Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease[1][2][3]. | ||||||
| Invitro | Dalazatide (ShK-186) (0-1000 pM) TFA 以剂量依赖的方式阻断卵巢特异性 GFP+ 效应记忆 T (Tem) 细胞中的 Kv1.3 电流，Kd 为 65 ± 5 pM[3]。Dalazatide (0-100 nM; 3 days) TFA 以剂量依赖的方式抑制 CCR7− T 细胞增殖[3]。Dalazatide (100 nM; 30 min) TFA 通过抑制钙信号通路固定炎症部位的效应记忆 T (Tem) 细胞，从而阻止 β1 整合素激活[3]。 Cell Proliferation Assay[3] Cell Line: | ||||||
| Name | Dalazatide TFA | ||||||
| Formula | C186H297F3N57PS7 | ||||||
| Molar Mass | 4556.10 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
Dalazatide TFA
CAS: F: C186H297F3N57PS7 W: 4556.10
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the stud
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.